CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | Greenstreet Yvonne Chief Executive Officer | Sale | −38 | $260.57 | $10K | 81,619 |
| 2025-02-14 | Greenstreet Yvonne Chief Executive Officer | Sale | −47 | $261.45 | $12K | 81,572 |
| 2025-02-14 | Greenstreet Yvonne Chief Executive Officer | Sale | −21 | $263.33 | $6K | 81,551 |
| 2025-02-14 | Greenstreet Yvonne Chief Executive Officer | Sale | −25 | $264.87 | $7K | 81,526 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −217 | $252.50 | $55K | 33,536 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −239 | $253.37 | $61K | 33,297 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −160 | $254.35 | $41K | 33,137 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −68 | $255.56 | $17K | 33,069 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −78 | $256.29 | $20K | 32,991 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −37 | $257.51 | $10K | 32,954 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −47 | $258.07 | $12K | 32,907 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −17 | $259.72 | $4K | 32,890 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −30 | $260.57 | $8K | 32,860 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −37 | $261.45 | $10K | 32,823 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −17 | $263.33 | $4K | 32,806 |
| 2025-02-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −20 | $264.87 | $5K | 32,786 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −145 | $252.50 | $37K | 14,839 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −164 | $253.37 | $42K | 14,675 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −110 | $254.35 | $28K | 14,565 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −47 | $255.56 | $12K | 14,518 |
Page 37 of 41 · 816 trades